ExonHit Therapeutics (Alternext: ALEHT) reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of alternative RNA splicing [1]. Study data demonstrate that exons are differently expressed in malignant and benign lesions, and alternative transcripts determine the molecular characteristics of breast malignancy.
More...